Mental Health Clinics in Ivel, KY Accepting Medicare
2 Mental Health Clinics found. Showing 1 - 2
 Renew Addiction Treatment Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 4963 Us Hwy 23 N, Suite 121, Ivel, KY 41642 Phone: 606-653-1505 |
Renew Behavioral Health Community/Behavioral Health Agency Medicare: Not Enrolled in Medicare Practice Location: 4963 Us Highway 23 S, Suite 121, Ivel, KY 41642 Phone: 606-653-1505 |
News Archive
KHN video: Health care battles to surge anew in 2011
In this video feature, Kaiser Health News reporters preview some of the big issues coming this year: The GOP's fight to repeal the law and what the party can offer instead; states' efforts to beat back growing Medicaid costs; consumers' troubles affording care (1/3).
Intra-CREATE grants awarded to support research on personalized medicine and cell therapy
Researchers from Critical Analytics for Manufacturing Personalized-Medicine, an interdisciplinary research group at Singapore-MIT Alliance for Research and Technology, MIT's research enterprise in Singapore, have been awarded Intra-CREATE grants from the National Research Foundation Singapore to help support research on retinal biometrics for glaucoma progression and neural cell implantation therapy for spinal cord injuries.
FDA approves human embryonic stem cells clinical trial for spinal cord injury treatment
Emerging Healthcare Solutions, Inc.: Last week, the US Food and Drug Administration gave their highly-anticipated approval for the first clinical trial using human embryonic stem cells (hESCs), which are the type of cells that can develop into all tissues of the body. Geron Corporation of Menlo Park, California, received the green light from the US FDA to use cells derived from hESCs to treat people with acute spinal cord injuries. Ten people will receive injections into the injury site of hESC-derived oligodendrocyte progenitor cells, which stimulate the growth of new and severed nerves and recoat damaged nerves with myelin. The hope is that the injections will help people recover function lost through injury, as seen in rodent studies in 2005.
Phase 3 data of VIVACITO study evaluating effect of T+O FDC in COPD presented at ATS conference
Boehringer Ingelheim today presented results of the VIVACITO® (NCT01559116) study, the first Phase 3 data to be reported from the TOviTO® clinical trial program, evaluating the effect of the fixed-dose combination of tiotropium and olodaterol (T+O FDC) delivered via the Respimat® inhaler on lung function in people with chronic obstructive pulmonary disease (COPD).
ACCORD Lipid trial: New research into atherogenic dyslipidemia in type 2 diabetes
Cardiovascular risk can be reduced by an additional 31 percent in type 2 diabetes patients with atherogenic dyslipidemia, the common combination of elevated triglycerides (TG, 204 mg/dL or 2.3 mmol/L or higher) and low levels of high-density lipoprotein cholesterol (HDL-C, 34 mg/dL or 0.88 mmol/L or lower).
› Verified 6 days ago